Pet IL-4 Therapeutic Antibody Development

Creative Biolabs provides specialized therapeutic antibody solutions designed to meet the unique needs of veterinary medicine. Our programs for IL-4 therapeutic antibody development are tailored to support innovation in the treatment of immune-mediated and allergic diseases in companion animals. By combining advanced discovery platforms with integrated preclinical evaluation, we help clients bring forward antibody-based therapies that improve health outcomes for dogs and cats.

Platforms in Therapeutic Antibody Discovery

We employ a range of complementary discovery platforms to ensure the identification of optimal therapeutic candidates. These discovery strategies allow Creative Biolabs to tailor the approach based on project scope, therapeutic goals, and species requirements.

• Phage Display: Our species-specific antibody libraries enable precise selection of high-affinity IL-4 binders that minimize immunogenic risk in pets. Phage display accelerates discovery timelines and broadens the pool of therapeutic options.
• Single-B Cell Sorting: This platform isolates naturally occurring, antigen-specific B cells. The antibodies serve as excellent starting points for engineering and optimization.
• Hybridoma Technology: Still an essential tool in antibody generation, hybridoma platforms provide stable, monoclonal antibody-producing clones that can be further optimized for improved pharmacokinetics and therapeutic efficacy.

Comprehensive Antibody Development Services

Our services span the entire therapeutic development pipeline. Each service is designed to advance candidate molecules closer to real-world therapeutic use, providing our clients with robust, data-driven results.

Antibody Characterization

Binding kinetics, epitope mapping, and functional assays establish the foundation for evaluating therapeutic relevance.

Antibody Engineering

Through advanced design strategies, we enhance stability, extend serum half-life, and optimize Fc-mediated functions.

Preclinical Evaluation

We conduct in vitro and in vivo studies that assess activity, safety, and tolerability in relevant models, ensuring translational potential.

Antibody Development

From candidate selection through scale-up and process development, Creative Biolabs ensures smooth progression toward veterinary research.

Discover How We Can Help - Request a Consultation

Why Focus on IL-4?

IL-4 is a cytokine central to the regulation of Th2 immune responses and IgE production, both of which contribute to allergic inflammation. In dogs, IL-4 overexpression is strongly linked with atopic dermatitis and chronic skin conditions characterized by pruritus, erythema, and secondary infections. Cats also demonstrate IL-4–driven pathology in allergic asthma and dermatitis, where immune hypersensitivity results in airway obstruction or persistent skin lesions. These diseases affect quality of life for both pets and owners, with limited long-term treatment options. Neutralizing IL-4 signaling through therapeutic antibodies offers a rational strategy to manage chronic inflammatory and allergic diseases in both species.

Mechanism of Action

IL-4 antibodies exert their therapeutic effect by binding to IL-4 and preventing it from interacting with the IL-4 receptor complex. This blockade interrupts downstream JAK-STAT signaling, leading to suppression of IgE class switching in B cells, reduced mast cell and eosinophil recruitment, and overall dampening of Th2-mediated inflammation. In veterinary contexts, this translates into alleviation of itching, improved skin barrier function, and reduction in airway hyperresponsiveness. By targeting the root cause of allergic inflammation rather than just the symptoms, IL-4 therapeutic antibodies provide a durable and specific treatment solution for companion animals.

Fig 1. Immunopathogenesis of canine atopic dermatitis and pharmacologic targets of anti-cytokine therapies.¹

Our Advantages

• Species-Specific Expertise: Our antibody discovery platforms are customized for canine and feline immune systems, ensuring therapeutic relevance.
• Integrated Pipeline: We provide end-to-end solutions that seamlessly connect discovery, engineering, and preclinical evaluation.
• Innovative Technology: Advanced bioinformatics, structural modeling, and screening assays accelerate timelines and enhance candidate success.
• Collaborative Approach: We work closely with clients to tailor strategies, ensuring alignment with scientific goals and regulatory expectations.

Partner with Creative Biolabs

Targeting IL-4 represents a powerful step toward advancing veterinary medicine and improving the lives of dogs and cats suffering from allergic and inflammatory diseases. Creative Biolabs is dedicated to supporting innovators and researchers with the technical expertise and platforms needed to develop next-generation therapies. Partner with us to bring your IL-4 therapeutic antibody projects from concept to preclinical validation and beyond. Connect with our team today to explore collaboration opportunities and make impactful progress in pet health.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Wichtowska, Agnieszka, and Małgorzata Olejnik. "Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis." International journal of molecular sciences vol. 26,22 10990. 13 Nov. 2025. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms262210990